FrancophonIA/ELRC3.0 huggingface dataset:
English: In patients with Cushing's disease, Signifor is given as an injection either under the skin (preferably at the top of the thigh and the belly) twice a day or into the buttock muscle every 4 weeks.
Estonian: Cushingi tõvega patsientidele manustatakse Signifori kas nahaaluse süstena (eelistatavalt reie ülaossa ja kõhupiirkonda) kaks korda ööpäevas või süstena tuharalihasesse iga 4 nädala järel.
English: months, the patient's response to treatment should be evaluated, and the dose adjusted as appropriate or treatment stopped if no benefit is seen.
Estonian: 2-4 kuu järel tuleb hinnata patsiendi ravivastust ja kui kasu ei täheldata, tuleb annust sobival viisil kohandada või ravi lõpetada.
English: This is a summary of the European public assessment report (EPAR) for Signifor.
Estonian: See on ravimi Signifor Euroopa avaliku hindamisaruande kokkuvõte.
English: For acromegaly, Signifor is given as an injection into the buttock muscle every 4 weeks.
Estonian: Akromegaalia korral manustatakse Signifori süstena tuharalihasesse iga 4 nädala järel.
English: Patients can inject themselves Signifor under the skin after they have been trained.
Estonian: Patsiendid võivad pärast väljaõppe saamist teha Signifori nahaaluseid süsteid endale ise.
English: Although the number of patients whose cortisol levels returns to normal is small, Signifor is expected tp help patients whose surgical treatments have failed or who cannot have surgery.
Estonian: Kuigi patsiente, kes saavutavad normaalse kortisoolisisalduse, on vähe, aitab Signifor arvatavalt patsiente, kellel operatsioon ei ole õnnestunud või see ei ole võimalik.
English: The most common side effects with Signifor (seen in more than 1 patient in 10) are hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick),
Estonian: Signifori kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on hüperglükeemia (vere suur glükoosisisaldus), diabeet, kõhulahtisus, kõhuvalu, iiveldus, kolelitiaas (sapikivid), süstekoha reaktsioonid ja väsimus.
English: For practical information about using Signifor, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Signifori kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Signifor is a medicine for treating adults with Cushing's disease (a condition caused by too much of a hormone called cortisol) and acromegaly (excessive growth, particularly of bones in the hands, feet and face caused by too much growth hormone).
Estonian: Signifor on ravim, mida kasutatakse Cushingi tõvega (haigus, mida põhjustab kortisooli (teatav hormoon) liiga suur sisaldus organismis) ja akromegaaliaga (ülemäärane luukasv, eelkõige käe-, jalaja näoluude puhul, mida põhjustab liigne kogus kasvuhormooni) täiskasvanute raviks.
English: In a second study in 150 adult patients which used the muscle injection, around 41% of patients responded to treatment within 7 months.
Estonian: Teises uuringus 150 täiskasvanud patsiendiga, kellele süstiti ravimit lihasesse, saavutas 7 kuu jooksul ravivastuse umbes 41% patsientidest.
English: For more information about treatment with Signifor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Signiforiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How is Signifor used?
Estonian: Kuidas Signifori kasutatakse?
English: Because the numbers of patients with these diseases are low, the diseases are considered ‘rare', and Signifor was designated an ‘orphan medicine' (a medicine used in rare diseases).
Estonian: Et nende haigustega patsiente on vähe ja need haigused esinevad harva, nimetati Signifor harvikravimiks.
English: Signifor is effective in reducing levels of growth hormone and IGF-1 (another hormone that is elevated in acromegaly patients).
Estonian: Signifor on efektiivne kasvuhormooni ja IGF-1 (teine hormoon, mille sisaldus on akromegaaliaga patsientidel normaalsest suurem) sisalduse vähendamisel.
English: Signifor is also effective in reducing levels of growth hormone in patients with acromegaly.
Estonian: Signifor on ühtlasi efektiivne kasvuhormooni sisalduse vähendamisel akromegaaliaga patsientidel.
English: What benefits of Signifor have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Signifori kasulikkus?
English: It contains the active substance pasireotide.
Estonian: Ravim sisaldab toimeainena pasireotiidi.
English: How does Signifor work?
Estonian: Kuidas Signifor toimib?
English: 34% of patients receiving 0.6 mg Signifor and 41% of patients receiving 0.9 mg Signifor partially responded to treatment, with their urine cortisol levels halved within 6 months.
Estonian: 34%-l Signifori annuses 0,6 mg saanud patsientidest ja 41%-l Signifori annuses 0,9 mg saanud patsientidest täheldati osalist ravivastust ning nende uriini kortisoolisisaldus oli 6 kuu jooksul vähenenud 50% võrra.
English: For the full list of restrictions with Signifor, see the package leaflet.
Estonian: Signifori kohta teatatud piirangute täielik loetelu on pakendi infolehel.
English: Signifor is available as a solution for injection under the skin and as a powder and liquid used for injection into the muscle.
Estonian: Signifori turustatakse nahaaluse süstelahusena ja intramuskulaarseks süstimiseks ette nähtud pulbri ja vedelikuna.
English: In a main study in 358 previously untreated adults, 31% of patients receiving Signifor had their growth hormone and IGF-1 levels reduced to pre-defined low levels after 1 year, compared with 19% of patients receiving octreotide, another somatostatin analogue.
Estonian: Põhiuuringus, milles osales 358 varem ravimata täiskasvanut, oli 31%-l Signifori saanud patsientidest kasvuhormooni ja IGF-1 sisaldus ühe aasta järel vähenenud eelmääratud madaltasemeni; oktreotiidi (samuti somatostatiini analoog) saanud patsientidest saavutas sama tulemuse 19%.
English: In a main study in 165 adult patients who were given the injection under the skin, 15% of patients receiving 0.6 mg Signifor and 26% of patients receiving 0.9 mg Signifor had normal urine cortisol levels within 6 months.
Estonian: Põhiuuringus 165 täiskasvanud patsiendiga, kes said Signifori nahaaluse süstena, oli 15%-l Signifori annuses 0,6 mg saanud patsientidest ja 26%-l Signifori annuses 0,9 mg saanud patsientidest uriini kortisoolisisaldus 6 kuu järel normaaltasemel.
English: In the second study in 198 patients whose disease had not been adequately controlled with surgery or other medical treatment, 15% of patients receiving Signifor 40 mg and 20% of patients receiving Signifor 60 mg achieved pre-defined reductions in hormone levels after 24 weeks, compared with none of the 68 patients given the somatostatin analogues octreotide or lanreotide.
Estonian: Teises uuringus, milles osales 198 patsienti, kelle haigus ei olnud piisaval määral allunud operatsioonile ega muudele ravimitele, oli 24 nädala järel hormoonide sisaldus eelmääratud tasemeni vähenenud 15%-l Signifori annuses 40 mg saanud patsientidest ja 20%-l Signifori annuses 60 mg saanud patsientidest, kusjuures somatostatiini analooge oktreotiidi või lanreotiidi saanud patsientidest ei saavutanud seda tulemust ükski 68 patsiendist.
English: Signifor is effective at reducing elevated cortisol levels patients with Cushing's disease.
Estonian: Signifor on efektiivne suurenenud kortisoolisisalduse vähendamisel Cushingi tõvega patsientidel.
English: For the full list of all side effects reported with Signifor, see the package leaflet.
Estonian: Signifori kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Signifor is effective at normalising cortisol levels in some patients with Cushing's disease.
Estonian: Signifor on osal Cushingi tõvega patsientidest efektiivne kortisoolisisalduse normaliseerimisel.
English: The medicine can only be obtained with a prescription.
Estonian: Signifor on retseptiravim.
English: Pregnant and breast-feeding women should avoid giving this medicine because it can affect the normal development of unborn and newborn children.
Estonian: Selle ravimi manustamist peavad vältima rasedad ja imetavad naised, sest see võib mõjutada sündimata laste ja vastsündinute normaalset arengut.
English: The full EPAR for Zycortal can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zycortali kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Around 25 days after the first injection the dog's response is evaluated before a second injection is given.
Estonian: Ligikaudu 25 päeva möödumisel esimesest süstest hinnatakse enne teise süste tegemist koera ravivastust.
English: In this study, Zycortal was shown to be at least as effective as the other similar medicine.
Estonian: Sellest uuringust nähtus, et Zycortal on vähemalt sama efektiivne kui teine sarnane ravim.
English: When satisfactory results are obtained then the treatment should continue to be given long-term using the same dose and interval between treatments.
Estonian: Rahuldavate tulemuste korral tuleks raviga pikaajaliselt jätkata, manustades sama annuse sama süstevahelise intervalliga.
English: Other information about Zycortal
Estonian: Muu teave Zycortali kohta
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zycortal's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Zycortali kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: A corticosteroid medicine is likely to be needed, in addition, to replace the cortisol.
Estonian: Lisaks on kortisooli asendamiseks tõenäoliselt vaja kortikosteroidravimit.
English: All dogs also received corticosteroids given by mouth.
Estonian: Samuti manustati kõigile koertele suukaudselt kortikosteroide.
English: The most common side effects with Zycortal (which may affect more than 1 in 10 dogs) are polydipsia (increase in water intake) and polyuria (increase in urine production).
Estonian: Zycortali kõige sagedamad kõrvaltoimed (võivad esineda enam kui 1 koeral 10st) on polüdipsia (veetarbimise suurenemine) ja polüuuria (uriini tekke suurenemine).
English: It works in the same way as aldosterone to retain sufficient water in the body (by retaining sodium and eliminating potassium).
Estonian: See toimib samamoodi nagu aldosteroon, hoides kehas piisavalt vett (säilitades naatriumi ja viies välja kaaliumi).
English: 90 days after start of treatment, 84% (92 out of 109) of Zycortal-treated dogs had improved clinical signs and normal sodium and potassium blood levels.
Estonian: 90 päeva pärast ravi alustamist oli Zycortaliga ravitud koertest 84%-l (92 koera 109st) kliinilised haigustunnused paranenud ning naatriumi ja kaaliumi sisaldus veres normaliseerunud.
English: The lack of aldosterone can cause fluid loss, dehydration and weight loss.
Estonian: Aldosterooni vaegus võib põhjustada vedelikukaotust, dehüdratsiooni ja kaalukaotust.
English: Zycortal may cause adverse effects on male reproductive organs and as a result can affect fertility.
Estonian: Zycortal võib põhjustada kõrvaltoimeid isasloomade reproduktiivorganitele ja selle tulemusena fertiilsusele.
English: Why is Zycortal approved?
Estonian: Miks Zycortal heaks kiideti?
English: Zycortal is used long-term to replace the missing aldosterone.
Estonian: Zycortali kasutatakse puuduva aldosterooni pikaajaliseks asendamiseks.
English: What is Zycortal and what is it used for?
Estonian: Mis on Zycortal ja milleks seda kasutatakse?
English: It is not intended to provide practical advice on how to use Zycortal.
Estonian: Hindamisaruandes ei anta Zycortali kasutamise praktilisi nõuandeid.
English: This is a summary of the European public assessment report (EPAR) for Zycortal.
Estonian: See on ravimi Zycortal Euroopa avaliku hindamisaruande kokkuvõte.
English: Zycortal is a veterinary medicine used to treat dogs with Addison's disease.
Estonian: Zycortal on veterinaarravim, mida kasutatakse Addisoni tõvega koerte raviks.
English: Zycortal is given as an injection under the skin at an initial dose of 2.2 mg/kg.
Estonian: Zycortali manustatakse nahaaluse süstena annuses 2,2 mg/kg.
English: Dogs with Addison's disease have insufficient levels of aldosterone in their blood and Zycortal is used to replace the missing hormone.
Estonian: Addisoni tõvega koerte veres ei ole piisavalt aldosterooni ning Zycortali kasutatakse puuduva hormooni asendamiseks.
English: What are the risks associated with Zycortal?
Estonian: Millised riskid Zycortaliga kaasnevad?
English: The effectiveness of Zycortal was investigated in a field study involving 152 dogs with Addison's disease.
Estonian: Zycortali efektiivsust uuriti väliuuringus 152 Addisoni tõvega koeral.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Zycortal, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Zycortali ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: The dose to be given and the interval between treatments depend on the dog's response as well as the blood levels of certain electrolytes (sodium and potassium).
Estonian: Manustatav annus ja süstevaheline intervall olenevad koera ravivastusest ning ka teatud elektrolüütide (naatrium ja kaalium) sisaldusest veres.
English: Addison's disease is a condition, known as hypoadrenocorticism, where the adrenal glands (located above the kidneys) do not produce enough of two steroid hormones, called cortisol and aldosterone.
Estonian: Addisoni tõbi ehk hüpoadrenokortitsism on haigus, mille korral neerupealised ei tooda piisavalt kahte steroidhormooni, kortisooli ja aldosterooni.
English: The European Commission granted a marketing authorisation valid throughout the EU for Zycortal on
Estonian: Euroopa Komisjon andis Zycortali müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 06/11/2015.
English: Desoxycortone pivalate is a synthetically produced steroid hormone very similar to the natural hormone aldosterone.
Estonian: Desoksükortoonpivalaat on sünteetiline steroidhormoon, mis on väga sarnane loomuliku hormooniga aldosteroon.
English: Zycortal was given by injection under the skin to 113 dogs and 39 dogs were given a similar medicine, which also contains desoxycortone pivalate, for injection into the muscle.
Estonian: 113 koerale manustati nahaaluse süstena Zycortali ja 39 koerale manustati lihasesisese süstena sarnast ravimit, mis sisaldab samuti desoksükortoonpivalaati.
English: For the full list of all side effects reported with Zycortal, see the package leaflet.
Estonian: Zycortali kohta teatatud kõrvaltoimete täielik loetelu on pakendi infolehel.
English: How does Zycortal work?
Estonian: Kuidas Zycortal toimib?
English: How is Zycortal used?
Estonian: Kuidas Zycortali kasutatakse?
English: For practical information about using Zycortal, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Zycortali kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: If irritation occurs, seek medical advice immediately and show the package leaflet or the label to the doctor.
Estonian: Ärrituse ilmnemisel tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: Desoxycortone pivalate
Estonian: Zycortal desoksükortoonpivalaat
English: Zycortal is available as a prolonged-release suspension for injection.
Estonian: Zycortali turustatakse toimeainet prolongeeritult vabastava süstesuspensioonina.
English: What benefits of Zycortal have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zycortali kasulikkus?
English: Zycortal can only be obtained with a prescription.
Estonian: Zycortal on retseptiravim.
English: This medicine may cause pain and swelling at the injection site if accidentally self-administered.
Estonian: Ravimi juhuslik manustamine iseendale võib põhjustada valu ja turset süstekohal.
English: Zycortal contains the active substance desoxycortone pivalate.
Estonian: Zycortali toimeaine on desoksükortoonpivalaat.
English: The measure of effectiveness was levels of antibodies before and after vaccination.
Estonian: Efektiivsuse põhinäitajaks oli antikehade sisaldus enne ja pärast vaktsineerimist.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Versican Plus Pi on 4 July 2014.
Estonian: Euroopa Komisjon andis Versican Plus Pi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 4. juulil 2014.
English: The effectiveness of Versican Plus Pi was investigated in a field study involving 129 dogs.
Estonian: Versican Plus Pi efektiivsust uuriti väliuuringus, kus osales 129 koera.
English: The vaccine is given to puppies from six weeks of age as an injection under the skin which is repeated three to four weeks later.
Estonian: Kutsikaid vaktsineeritakse alates kuue nädala vanusest subkutaanse süstega, teine süst tehakse kolme kuni nelja nädala pärast.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Versican Plus Pi exceed the risks for the approved indications and recommended that Versican Plus Pi be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustustel on vaktsiini Versican Plus Pi kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini Versican Plus Pi müügiloa.
English: For revaccination, a single dose of Versican Plus Pi is required annually.
Estonian: Kordusvaktsineerimiseks manustatakse üks annus vaktsiini Versican Plus Pi üks kord aastas.
English: Versican Plus Pi is a vaccine.
Estonian: Versican Plus Pi on vaktsiin.
English: The field study involved the larger vaccine combinations Versican Plus DHPPi/L4 and Versican Plus DHPPi/L4R, which are also intended to protect against kennel cough in addition to other diseases, to demonstrate effectiveness of Versican Plus Pi.
Estonian: Versican Plus Pi efektiivsuse tõestamiseks hõlmas uuring laiema toimega kombineeritud vaktsiine Versican Plus DHPPi/L4 ja Versican Plus DHPPi/L4R, mis on lisaks teistele haigustele ette nähtud ka kaitsmiseks trahheobronhiidi eest.
English: When Versican Plus Pi is given to dogs, the animals' immune system recognises the viruses as ‘foreign' and makes antibodies against them.
Estonian: Kui koertele manustatakse vaktsiini Versican Plus Pi, peab immuunsüsteem viiruseid võõraks ning tekitab nende vastu antikehi.
English: The most common side effect (seen in more than 1 in 100 dogs) with Versican Plus Pi is a short lived swelling of up to 5 cm which may occur at the injection site after vaccination.
Estonian: Versican Plus Pi kõige sagedam kõrvalnäht (esinenud enam kui 1 koeral 100st) on kuni 5 cm suurune mööduv turse süstekohal.
English: Versican Plus Pi is a veterinary vaccine that contains live attenuated (weakened) canine parainfluenza virus type 2.
Estonian: Versican Plus Pi on veterinaarvaktsiin, mis sisaldab koerte 2. tüüpi paragripiviiruse nõrgestatud elusvorme.
English: The field study showed that vaccination with Versican Plus Pi resulted in protective levels of antibodies for parainfluenza virus ranging from 73 to 97%.
Estonian: Väliuuring näitas, et pärast vaktsineerimist vaktsiiniga Versican Plus Pi oli uuringus 73-97% koeri, kelle organismis oli piisavalt antikehi paragripiviiruse vastu.
English: Why has Versican Plus Pi been approved?
Estonian: Miks Versican Plus Pi heaks kiideti?
English: This will help protect them against kennel cough.
Estonian: See aitab loomi trahheobronhiidi eest kaitsta.
English: What is Versican Plus Pi?
Estonian: Mis on Versican Plus Pi?
English: Other information about Versican Plus Pi:
Estonian: Muu teave Versican Plus Pi kohta
English: What is the risk associated with Versican Plus Pi?
Estonian: Mis riskid vaktsiiniga Versican Plus Pi kaasnevad?
English: In the future, if the animals are exposed to this infection, the immune system will be able to respond more quickly.
Estonian: nakkusega hiljem uuesti kokku, tekivad antikehad kiiremini.
English: Canine parainfluenza virus vaccine (live attenuated)
Estonian: Versican Plus Pi koerte paragripiviiruse vaktsiin (elus, nõrgestatud)
English: Versican Plus Pi is used to protect dogs against canine parainfluenza virus, which causes kennel cough.
Estonian: Vaktsiini Versican Plus Pi kasutatakse koerte kaitsmiseks trahheobronhiiti põhjustava koerte paragripiviiruse eest.
English: How has Versican Plus Pi been studied?
Estonian: Kuidas vaktsiini Versican Plus Pi uuriti?
English: Versican Plus Pi is available as a lyophilisate (freeze-dried pellet) with a solvent that are made up into a suspension for injection.
Estonian: Vaktsiini Versican Plus Pi turustatakse süstesuspensiooni lüofilisaadi (külmkuivatatud graanulid) ja lahustina.
English: What benefit has Versican Plus Pi shown during the studies?
Estonian: Milles seisneb uuringute põhjal Versican Plus Pi kasulikkus?
English: The virus in Versican Plus Pi is alive but has been attenuated (weakened) so that does not cause disease.
Estonian: Versican Plus Pi sisaldab viiruste elusvorme, mida on haiguse tekke takistamiseks nõrgestatud.
English: What is Versican Plus Pi used for?
Estonian: Milleks vaktsiini Versican Plus Pi kasutatakse?
English: How does Versican Plus Pi work?
Estonian: Kuidas Versican Plus Pi toimib?
English: EU/1/14/953/001 Tasermity
Estonian: EU/1/14/953/001
English: 180 tablets l t o r
Estonian: 180 tabletti l n a
English: MA (EU) number (Invented) name Strength Pharmaceutical Form
Estonian: (Väljamõeldud) nimetus Tugevus Ravimvorm Manustamistee Sisepakendi iseloomustus
English: 800 mg Film-coated tablet Oral use bottle (HDPE)
Estonian: 800 mg Õhukese polümeerikattega tablett
English: Pack size
Estonian: Tasermity
English: --1 Virus titer no less than of 5 x 107 Inf.U
Estonian: --1 virus tiiter on vähemalt 5 x 107 IÜ
English: Subcutaneous use vial (glass)
Estonian: Süstesuspensioon Subkutaanne Viaal (klaas) 0,5 ml
English: What is Kalbitor?
Estonian: Mis on Kalbitor?
English: Withdrawal of the marketing authorisation application for Kalbitor (ecallantide) EMA/888548/2011
Estonian: Teave müügiloa taotluse tagasivõtmise kohta: Kalbitor (ekallantiid) EMA/888548/2011
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Kalbitor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation causes the swelling attacks seen in angioedema.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Kalbitori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The application was withdrawn after ‘day 181'.
Estonian: Taotluse menetlemine oli kestnud 181 päeva, kui ettevõte taotluse tagasi võttis.
English: The company has informed the CHMP that the withdrawal will not have any consequences for patients enrolled in any trials.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu kliinilistes uuringutes osalevaid patsiente.
English: Kalbitor is a medicine that contains the active substance ecallantide.
Estonian: Kalbitor on ravim, mis sisaldab toimeainena ekallantiidi.
English: How is Kalbitor expected to work?
Estonian: Milline on Kalbitori eeldatav toime?
English: Kalbitor was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 18 December 2002 for the treatment of angioedema.
Estonian: Kalbitor nimetati 18. detsembril 2002 angioödeemi harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: Other measures included the time that it took for the attack to resolve.
Estonian: Teiste näitajate seas oli hoo taandumiseni kulunud aeg.